[Skip to Content]
[Skip to Content Landing]
May 2, 1931


JAMA. 1931;96(18):1505-1506. doi:10.1001/jama.1931.02720440053011

Since the discovery of the etiologic relationship of the pneumococcus to pneumonia, the search for an effective antipneumococcus serum has continued unabated. Little progress, however, was made in this direction until 1913, when the biologic classification of pneumococci by Dochez and Gillespie1 provided a rational basis for modern serum therapy in this disease. Shortly after, Cole2 made his first report on the therapeutic value of type I antipneumococcus serum in the treatment of pneumococcus type I pneumonia. These investigators also experimented with immune serums for type II and type III pneumonia, but with little practical success. In 1929, Cole3 reported the statistical results of a series of 431 cases of type I pneumonia that had been treated with type I serum at the Hospital of the Rockefeller Institute. The mortality rate for this series of cases was only 10.2 per cent. Comparing this with the usual death

First Page Preview View Large
First page PDF preview
First page PDF preview